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We are pleased to serve as editors of this special issue. We
were gratiﬁed by the excellent response to the call for papers
and the high quality of the eleven manuscripts that were
ultimately accepted for this special issue.
This issue begins, as is appropriate, with a historical
perspective by R. M. Friedman and S. Contente from the
Uniformed Services University of the Health Sciences on
treatment of chronic hepatitis C with interferon, followed
by a paper by C.-H. Chen and M.-L. Yu from Kaohsiung
Medical University tracing the evolution of interferon-based
therapy, including the addition of ribavirin and pegylation
of interferon. Both of these papers provide an interesting
capsule of where we began with the initial recognition of
the antiviral activity of interferon in 1957, followed by the
evolution interferon-based therapy of chronic hepatitis C
with the addition of ribavirin in the mid-1990s and the
demonstration of the superiority of pegylated interferon
(peginterferon) plus ribavirin in the early 2000s. The sus-
tained virologic response (SVR) rate increased from 8%–9%
with interferon monotherapy to 30% in genotype 1 patients
with the addition of ribavirin, and then to 40%–50% with
the transition to peginterferon plus ribavirin. As noted in
several papers in this special issue, we are on the threshold
of increasing the SVR rate in 2011 up to 65%–75% with
the addition of a protease inhibitor to the standard of care
with peginterferon plus ribavirin. Thus, advances in the
treatment of chronic hepatitis C continue to march forward,
withSVRratesincreasingfromlessthan10%withinterferon
monotherapy to close to 75% in the very near future with
triple therapy using a protease inhibitor. What is remarkable
is that this progress has all taken place within the past 20
years. In the next paper, T. Kagawa and E. Keeﬀer e v i e w
the recent literature evaluating the long-term outcomes
of antiviral therapy in patients with chronic hepatitis C
that convincingly demonstrate the impact of interferon-
based treatment of chronic hepatitis C. The published data
shows slowed disease progression in patients who achieve an
SVR, including improved inﬂammation and ﬁbrosis scores
on follow-up biopsy, reduced incidence of hepatocellular
carcinoma,andprolongedlifeexpectancywithreducedliver-
related deaths. Thus, the progress in treatment over the past
20 years is paying dividends to our patients.
The prediction of response to interferon-based therapy is
an important issue for patients considering embarking on a
course of therapy, and providers of care continue to improve
theirabilitytopredictsuccessinindividualpatientsbytaking
into account baseline host (age, race, gender, histology (stage
of ﬁbrosis and presence or absence of steatosis), body weight,
insulin resistance, and IL28B genotype) and viral factors
(genotype and HCV RNA level). A number of papers in
this special issue address predictors of viral response. N.
Izumi et al. provide a thorough and scholarly review of
the various factors that predict an SVR and their relative
importance. R. Cubillas et al. from Southwestern Medical
Center in Dallas elegantly demonstrate that tumor necrosis
factor receptor 1 is upregulated in dendritic cells in patients
with chronic hepatitis C who respond to therapy. Although
not clinically available, R. Kubota et al. demonstrate that2 Hepatitis Research and Treatment
erythrocyte ribavirin levels can predict which patients are
more likely to achieve an early virologic response after 12
weeks of treatment.
A number of miscellaneous papers in this special issue
address the treatment of chronic hepatitis C in a number
of special populations. M. Numata et al. from several
Japanese medical centers treated 122 patients with genotype
1 infection and demonstrated by multivariate analysis that
adherence to peginterferon and ribavirin was the only
predictor of SVR. The rate of SVR fell sharply when exposure
to peginterferon was less than 80% and also decreased in a
stepwise fashion when ribavirin exposure was 60%–80% and
less than 60% compared with greater than 80%. D. F. Meyer
et al. from several New York medical centers report that daily
high-dose consensus interferon (24µg) plus weight-based
ribavirin was not successful in genotype 1 nonresponders to
priortherapyandwasassociatedwithsubstantialsideeﬀects.
Y. Y. Hwang and R. H. S. Liang from QueenMary Hospital in
Hong Kong review antiviral therapy in hematologic patients
and point out that the published literature demonstrates
that HCV RNA levels increase during chemotherapy and
immunosuppression and that there is a risk of rebound
immunity against hepatitis C with liver injury after dis-
continuation of immunosuppression. They recommend that
close monitoring during chemotherapy is appropriate and
that antiviral therapy with peginterferon and ribavirin
should be deferred until complete of chemotherapy and
recovery of immunity. H. Weclawiak et al. focus on the
management of chronic hepatitis C during hemodialysis
and reinforce the recommendation to treat during dialysis,
as there is a high rate of SVR that eliminates recurrence
of HCV infection after kidney transplantation. They also
reinforce the standard recommendation not to treat chronic
hepatitis C after kidney transplantation because of the high
risk of acute allograft rejection. Finally, Y. Sugawara et al.
from the University of Tokyo provide a thorough review
of the controversies and challenges in the management of
recurrent chronic hepatitis C after liver transplantation.
Although there is no general consensus on who, when and
how to treat, the overall SVR rate is 25%–45% with standard
peginterferon plus ribavirin, in spite of a high prevalence
of intolerability. The newer antiviral therapies in 2011 may
bring greater success in the management of patients with
posttransplant recurrent HCV infection.
The editors are conﬁdent that the readers will enjoy
reading this special issue and the diverse topics that are
expertly reviewed.
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